Anterix (ATEX) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Anterix (ATEX) over the last 12 years, with Q4 2025 value amounting to $132.6 million.

  • Anterix's Current Deferred Revenue rose 518.4% to $132.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $132.6 million, marking a year-over-year increase of 518.4%. This contributed to the annual value of $124.7 million for FY2025, which is 201.29% up from last year.
  • According to the latest figures from Q4 2025, Anterix's Current Deferred Revenue is $132.6 million, which was up 518.4% from $130.4 million recorded in Q3 2025.
  • In the past 5 years, Anterix's Current Deferred Revenue registered a high of $132.6 million during Q4 2025, and its lowest value of $737000.0 during Q2 2021.
  • Its 5-year average for Current Deferred Revenue is $72.5 million, with a median of $61.1 million in 2022.
  • As far as peak fluctuations go, Anterix's Current Deferred Revenue skyrocketed by 727354.14% in 2022, and later plummeted by 8875.62% in 2023.
  • Quarter analysis of 5 years shows Anterix's Current Deferred Revenue stood at $1.5 million in 2021, then skyrocketed by 4052.03% to $61.4 million in 2022, then crashed by 88.76% to $6.9 million in 2023, then surged by 1726.97% to $126.1 million in 2024, then rose by 5.18% to $132.6 million in 2025.
  • Its Current Deferred Revenue was $132.6 million in Q4 2025, compared to $130.4 million in Q3 2025 and $128.2 million in Q2 2025.